Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Lenvatinib + PD-1 Antibody in Advanced HCC
NCT03803254Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2019
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Planned start Jan 2019; status: withdrawn.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03803254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803254.